Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-392 versus docetaxel in metastatic NSCLC after PD-1/PD-L1 inhibitor progression
ChiCTR2500103006Phase 3Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gotistobart in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: overall survival. Started May 2025; status: recruiting.
02
Drugs
gotistobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500103006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103006.